Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)

Trial Profile

Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2018

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Polycythaemia vera
  • Focus Registrational; Therapeutic Use
  • Acronyms RESPONSE
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 04 Jul 2018 Results comparing data from this trial with the data from GEMFINI patient registry were announced at the 23rd European Society of Hematology (EHA) 2018, as reported in a Novartis Media release.
    • 04 Jul 2018 Results comparing data from this trial with the data from GEMFINI patient registry published in the Novartis Media Release
    • 15 Jun 2018 Accordimg to Novartis Media release, new findings were presented at the 23rd Congress of the European Hematology Association (EHA)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top